Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs
- PMID: 12707005
- DOI: 10.1016/S0165-6147(03)00067-1
Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs
Abstract
The remarkable progress made by molecular biology and molecular genetics during the past decade, and the advent of the novel tools of genomics and proteomics, are expected to reveal differential expression profiles of thousands of genes and proteins involved in the degeneration of dopamine-containing cells in Parkinson's disease and allow more focused treatments according to individual genotypes. Of particular interest is the application of microarrays in drug discovery and design to identify 'fingerprints' as potential candidate targets for drug intervention. The major microarray findings relevant to Parkinson's disease and its neurotoxin-induced animal and cell models will be discussed, with particular reference to the neuroprotective therapeutic potential that could arise from the development of drugs 'a la carte'.
Similar articles
-
Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs.Drug Discov Today. 2004 Dec 15;9(24 Suppl):S37-44. Drug Discov Today. 2004. PMID: 23573659
-
Evaluation of animal models of Parkinson's disease for neuroprotective strategies.J Neurosci Methods. 2004 Oct 30;139(2):121-43. doi: 10.1016/j.jneumeth.2004.08.004. J Neurosci Methods. 2004. PMID: 15488225 Review.
-
Designing neuroprotection trials in Parkinson's disease.Ann Neurol. 2003;53 Suppl 3:S100-7; discussion S107-9. doi: 10.1002/ana.10484. Ann Neurol. 2003. PMID: 12666102 Review.
-
Contribution of genomics and proteomics in understanding the role of modifying factors in Parkinson's disease.Indian J Biochem Biophys. 2006 Apr;43(2):69-81. Indian J Biochem Biophys. 2006. PMID: 16955754 Review.
-
Parkinson's disease, insulin resistance and novel agents of neuroprotection.Brain. 2013 Feb;136(Pt 2):374-84. doi: 10.1093/brain/aws009. Epub 2012 Feb 17. Brain. 2013. PMID: 22344583 Review.
Cited by
-
Genomics and proteomics in solving brain complexity.Mol Biosyst. 2013 Jul;9(7):1807-21. doi: 10.1039/c3mb25391k. Epub 2013 Apr 24. Mol Biosyst. 2013. PMID: 23615871 Free PMC article. Review.
-
Systems Pharmacology Based Study of the Molecular Mechanism of SiNiSan Formula for Application in Nervous and Mental Diseases.Evid Based Complement Alternat Med. 2016;2016:9146378. doi: 10.1155/2016/9146378. Epub 2016 Dec 12. Evid Based Complement Alternat Med. 2016. PMID: 28058059 Free PMC article.
-
Ropinirole alters gene expression profiles in SH-SY5Y cells: a whole genome microarray study.Braz J Med Biol Res. 2016 Feb;49(2):e4857. doi: 10.1590/1414-431X20154857. Epub 2016 Jan 19. Braz J Med Biol Res. 2016. PMID: 26785691 Free PMC article.
-
Baicalin Represses C/EBPβ via Its Antioxidative Effect in Parkinson's Disease.Oxid Med Cell Longev. 2020 May 21;2020:8951907. doi: 10.1155/2020/8951907. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 32566108 Free PMC article.
-
Inflammation as a causative factor in the aetiology of Parkinson's disease.Br J Pharmacol. 2007 Apr;150(8):963-76. doi: 10.1038/sj.bjp.0707167. Epub 2007 Mar 5. Br J Pharmacol. 2007. PMID: 17339843 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous